On August 11, 2022, Miri Halperin Wernli, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she is resigning from the Board as of August 11, 2022. On August 11, 2022, the Board adopted a resolution to increase the size of the Board from five members to six members effective as of August 11, 2022. On August 11, 2022, the Board appointed Suzanne Bruhn, Ph.D. to the Board, filling the vacancy left by the resignation of Dr. Halperin Wernli, effective immediately.

Dr. Bruhn will serve until such time as her respective successor is duly elected and qualified at the Company's 2023 Annual Meeting or until her earlier death, resignation, retirement, disqualification or removal. Dr. Bruhn will also serve as a member of the Nominating and Corporate Governance Committee and the Compensation Committee of the Board. Suzanne Bruhn, Ph.D., is the President and Chief Executive Officer of Tiaki Therapeutics, a role she has held since May 2019.

Prior to that, Dr. Bruhn served as President and Chief Executive Officer of Proclara Biosciences Inc., from April 2017 until September 2018. Prior to that, Dr. Bruhn served as President and Chief Executive of Promedior Inc., from 2012 until 2015. Dr. Bruhn also serves on the board of directors of Vigil Neuroscience, since July 2022, Travere Therapeutics Inc., since April 2020, and Pliant Therapeutics, since July 2016.

Dr. Bruhn previously served as a member of the board of directors of Aeglea BioTherapeutics, Inc, from February 2017 through August 2020, Novelion Therapeutics, Inc, from October 2017 through January 2020, Raptor Pharmaceuticals Corp., from April 2011 until it was acquired by Horizon Pharma plc in October 2016, and Avalo Therapeutics Inc. from April 2020 to December 2021. Dr. Bruhn holds a Bachelors degree in chemistry from Iowa State University, a Ph.D. in chemistry from the Massachusetts Institute of Technology and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School. On August 11, 2022, the Board appointed Roger Crystal, M.D. to the Board, effective immediately.

Dr. Crystal will serve until such time as his respective successor is duly elected and qualified at the Company's 2023 Annual Meeting or until his earlier death, resignation, retirement, disqualification or removal. Dr. Crystal will also serve as a member of the Nominating and Corporate Governance Committee and Compensation Committee of the Board. Roger Crystal, M.D., is the President, Chief Executive Officer and Director for Opiant Pharmaceuticals, a position he has held since August 2009.

Dr. Crystal previously served as the Chief Business Officer for ImaginAb, from July 2004 to February 2016. He began his business career with roles at Goldman Sachs, A.T. Kearney, and GE Healthcare. He holds a BMedSci in Physiology and an MD from the University of Birmingham, UK and an MBA from the London Business School.

Prior to his business career, Dr. Crystal worked for several years as a surgeon, specializing in ear, nose, and throat, head and neck surgery at leading institutions including Imperial College Healthcare, London and was awarded Membership of The Royal College of Surgeons of England (MRCS).